drug · small molecule
doxorubicin
Phase 2updated 6mo agoby Sunstate Biosciences LLC🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 8- tagApproval60 co-mentions · 30 sources
- drugDoxil59 co-mentions · 30 sources
- drugDOXIL (LIPOSOMAL)59 co-mentions · 30 sources
- drugDoxorubicin Teva31 co-mentions · 31 sources
- drugFarmiblastina31 co-mentions · 31 sources
- drugdoxorubicin hydrochloride30 co-mentions · 30 sources
- drugCHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone]1 co-mentions · 1 sources
- companyCity of Hope1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 64 investigational indications.
targets
DNA topoisomerase 2-alpha
all catalysts(0)
nothing on the calendar yet
Trials studying doxorubicin
- phase2Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
- phase3A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
- phase2A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
- phase2IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
- phase3A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
- phase2Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- phase3A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- phase3A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
News(6)
- ‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrenceA standard chemotherapy drug loaded in nanoparticles has been able to penetrate the blood-brain barrier when administered shortly after resection of the tumor, new research has suggested.fiercebiotech · 3mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 6mo ago
- Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast CancerTreatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.onclive · 6mo ago
- Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin LymphomaAlex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.onclive · 6mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 6mo ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that